EASYGEN EASY workflow integration for GENe therapy
- Coordinator
- Fresenius Se & Co Kgaa, Germany
- Runs
- 1 April 2025 to 31 March 2030
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €12.9m
- Partners
- 21 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101194710
What the project is doing
In the project's own words, from its summary on CORDIS.
More than 20 million new patients world-wide are diagnosed with cancer every year, and prediction for 2050 foresee over 35 million cancer cases, reflecting the population ageing and growth with a tremendous burden on the health care system. A global WHO survey with 115 participating countries has shown, that only 39% can cover basic cancer care management, financed as core health service. This reveals significant global inequities between high GNP and low- and middle-income countries, which is also reflected in country-specific cancer patient outcomes.
Hence, there is a strong need for emerging technologies, that democratize access to cancer treatment, reduce the disparities in cancer care, and significantly reduce the burden on the healthcare workforce. Chimeric Antigen Receptor T-cells are considered as cutting-edge treatment for cancer, but currently only for hematologic malignancies. And although the efficacy is very promising the number of European patients having access to CAR-T treatment is still very limited due to high costs and complex manufacturing and logistic processes.
The public private partnerhsip EASYGEN will develop an automated, modular point-of-care cell- and gene-therapy platform, that will allow for the first time hospital on-site CAR-T manufacturing. Designed as a closed, modular, one-stop solution, the device aims to reduce manufacturing time significantly to less than 24 hours and treatment costs by 50%. In a user-centric, co-creation approach, the device will be holistically integrated in a standard hospital workflow, hence empowering healthcare systems to provide CAR-T treatment in any standard hospital setting, capable of conducting leukapheresis.
Its modular set-up will ensure adaptability to different ATMPs including solid tumours. Therewith, EASYGEN will initiate a paradigm shift in the CAR-T market, paving the way to a greater democratized cancer treatment access and improving the patient’s quality of life and overall outcome.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fresenius Se & Co Kgaa | Bad Homburg | Germany | Coordinator |
| Cancer Patients Europe | Bruxelles / Brussel | Belgium | Associatedpartner |
| Charles River Discovery Research Services Germany GmbH | Freiburg | Germany | Participant |
| Frankfurt School of Finance & Management Gemeinnutzige GmbH | Frankfurt Am Main | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Fresenius Kabi Deutschland GmbH | Bad Homburg | Germany | Associatedpartner |
| Helmholtz-Zentrum Dresden-Rossendorf eV | Dresden | Germany | Participant |
| Helios Klinikum Berlin-Buch GmbH | Berlin | Germany | Participant |
| Pro-Liance Global Solutions GmbH | Munster | Germany | Participant |
| T-Curx GmbH | Wurzburg | Germany | Associatedpartner |
| Tq Therapeutics GmbH | Munchen | Germany | Participant |
| Danmarks Tekniske Universitet | Kongens Lyngby | Denmark | Participant |
| Idcq Hospitales Y Sanidad SL | Madrid | Spain | Associatedpartner |
| Universidad De Navarra | Pamplona | Spain | Participant |
| Cellix Limited | Dublin | Ireland | Participant |
| Bar Ilan University | Ramat Gan | Israel | Participant |
| European Society for Blood and Marrow Transplantation | Leiden | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Participant |
| University of Glasgow | Glasgow | United Kingdom | Participant |
| Fenwal Inc | Lake Zurich | United States | Participant |
| Kytopen Corp. | Cambridge | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI